Familial Hypercholesterolemia: Screening, Diagnosis, and Treatment

Familial hypercholesterolemia is common enough — roughly 1 in 250 people — and dangerous enough that the first sign is often a heart attack before 50. This American Family Physician editorial is a practical attempt to catch it earlier, in the one setting where most patients are actually seen: primary care.

The condition is an inherited disorder that keeps LDL cholesterol markedly elevated from birth. The severe homozygous form announces itself with physical signs like xanthomas; the far more common heterozygous form hides in plain sight, with no outward findings and a normal-looking patient until an early cardiovascular event.

The editorial’s value is in cutting through conflicting screening advice. It lays the major positions side by side — the USPSTF’s verdict of insufficient evidence to screen children under 20, against the NHLBI, AAP, and AHA recommendations for universal screening at ages 9 to 11 — and offers family physicians a pragmatic path: use the validated Dutch Criteria, act on an LDL above 190 mg/dL paired with a family history of premature disease, and run cascade screening through relatives once a case is found. On treatment it spans the full ladder, from lifestyle and statins to PCSK9 inhibitors, lomitapide, and evinacumab, with newer agents in trials.

The honest tension is the screening disagreement itself: a clinician following the letter of the USPSTF and one following the AHA will behave differently with the same child.

We rate the evidence moderate. This is an editorial synthesizing guidelines and reviews rather than original data, but it is grounded in solid sources and aimed squarely at the practical question — how does a busy generalist find the patients whose genes have been quietly raising their risk for decades?